GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Price-to-Free-Cash-Flow
中文

Innoviva (Innoviva) Price-to-Free-Cash-Flow : 8.58 (As of Apr. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva Price-to-Free-Cash-Flow?

As of today (2024-04-25), Innoviva's share price is $15.16. Innoviva's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.77. Hence, Innoviva's Price-to-Free-Cash-Flow Ratio for today is 8.58.

The historical rank and industry rank for Innoviva's Price-to-Free-Cash-Flow or its related term are showing as below:

INVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.77   Med: 8.35   Max: 141.14
Current: 8.6

During the past 13 years, Innoviva's highest Price-to-Free-Cash-Flow Ratio was 141.14. The lowest was 2.77. And the median was 8.35.

INVA's Price-to-Free-Cash-Flow is ranked better than
84.98% of 213 companies
in the Biotechnology industry
Industry Median: 31 vs INVA: 8.60

Innoviva's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.39. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $1.77.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Innoviva was -23.50% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -16.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -2.40% per year.

During the past 13 years, Innoviva's highest 3-Year average Free Cash Flow per Share Growth Rate was 181.90% per year. The lowest was -16.30% per year. And the median was 14.80% per year.


Innoviva Price-to-Free-Cash-Flow Historical Data

The historical data trend for Innoviva's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Price-to-Free-Cash-Flow Chart

Innoviva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.24 4.49 4.49 6.26 9.91

Innoviva Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.26 8.22 11.31 8.84 9.91

Competitive Comparison of Innoviva's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Innoviva's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Innoviva's Price-to-Free-Cash-Flow falls into.



Innoviva Price-to-Free-Cash-Flow Calculation

Innoviva's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=15.16/1.766
=8.58

Innoviva's Share Price of today is $15.16.
Innoviva's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.77.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Innoviva  (NAS:INVA) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Innoviva Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Innoviva's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva (Innoviva) Business Description

Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Executives
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511